Amarin Corporation plc (NASDAQ: AMRN) Stock Competitors & Peer Comparison
See AMRN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMRN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMRN | $11.61 | +0.30% | 241.1M | -116.55 | -$0.10 | N/A |
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
AMRN vs LLY Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while LLY trades at $1,354.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas LLY's P/E ratio is 43.57. In terms of profitability, AMRN's ROE is -0.04%, compared to LLY's ROE of +0.84%. Regarding short-term risk, AMRN is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
AMRN vs JNJ Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas JNJ's P/E ratio is 25.74. In terms of profitability, AMRN's ROE is -0.04%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, AMRN is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
AMRN vs ABBV Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas ABBV's P/E ratio is 28.59. In terms of profitability, AMRN's ROE is -0.04%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, AMRN is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
AMRN vs MRK Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, MRK has a market cap of 362B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas MRK's P/E ratio is 45.70. In terms of profitability, AMRN's ROE is -0.04%, compared to MRK's ROE of +0.05%. Regarding short-term risk, AMRN is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check MRK's competition here
Novartis AG (NYSE: NVS)
AMRN vs NVS Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, NVS has a market cap of 307B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas NVS's P/E ratio is 18.71. In terms of profitability, AMRN's ROE is -0.04%, compared to NVS's ROE of +0.25%. Regarding short-term risk, AMRN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
AMRN vs AZN Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas AZN's P/E ratio is 20.13. In terms of profitability, AMRN's ROE is -0.04%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMRN is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
AMRN vs AMGN Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while AMGN trades at $460.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas AMGN's P/E ratio is 20.57. In terms of profitability, AMRN's ROE is -0.04%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, AMRN is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
AMRN vs GILD Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas GILD's P/E ratio is -427.74. In terms of profitability, AMRN's ROE is -0.04%, compared to GILD's ROE of -0.22%. Regarding short-term risk, AMRN is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
AMRN vs NVO Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas NVO's P/E ratio is 10.03. In terms of profitability, AMRN's ROE is -0.04%, compared to NVO's ROE of +0.54%. Regarding short-term risk, AMRN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
AMRN vs PFE Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas PFE's P/E ratio is 9.63. In terms of profitability, AMRN's ROE is -0.04%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMRN is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
AMRN vs BMY Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while BMY trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas BMY's P/E ratio is 10.48. In terms of profitability, AMRN's ROE is -0.04%, compared to BMY's ROE of +0.44%. Regarding short-term risk, AMRN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check BMY's competition here
Sanofi (NASDAQ: SNY)
AMRN vs SNY Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while SNY trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas SNY's P/E ratio is 10.24. In terms of profitability, AMRN's ROE is -0.04%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMRN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check SNY's competition here
GSK plc (NYSE: GSK)
AMRN vs GSK Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas GSK's P/E ratio is 10.87. In terms of profitability, AMRN's ROE is -0.04%, compared to GSK's ROE of +0.23%. Regarding short-term risk, AMRN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
AMRN vs CELG-RI Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMRN's ROE is -0.04%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, AMRN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
AMRN vs BIIB Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas BIIB's P/E ratio is 15.69. In terms of profitability, AMRN's ROE is -0.04%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, AMRN is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
AMRN vs HZNP Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMRN's ROE is -0.04%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMRN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
AMRN vs GRFS Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while GRFS trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas GRFS's P/E ratio is 9.69. In terms of profitability, AMRN's ROE is -0.04%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, AMRN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
AMRN vs OGN Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas OGN's P/E ratio is 4.13. In terms of profitability, AMRN's ROE is -0.04%, compared to OGN's ROE of +0.22%. Regarding short-term risk, AMRN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMRN.Check OGN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
AMRN vs MIRA Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas MIRA's P/E ratio is -0.38. In terms of profitability, AMRN's ROE is -0.04%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AMRN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
AMRN vs SCLX Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas SCLX's P/E ratio is -0.04. In terms of profitability, AMRN's ROE is -0.04%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMRN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
AMRN vs SCLXW Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMRN's ROE is -0.04%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMRN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
AMRN vs BDSIW Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMRN's ROE is -0.04%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMRN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
AMRN vs CRXT Comparison November 2026
Amarin Corporation plc (NASDAQ: AMRN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMRN stands at 241.1M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMRN is priced at $11.61 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMRN currently has a P/E ratio of -116.55, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMRN's ROE is -0.04%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMRN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMRN.Check CRXT's competition here